BlossomHill Therapeutics Files for Nasdaq IPO, Aims to Raise Up to $133 Million

BlossomHill Therapeutics, Inc. has filed plans for an initial public offering on the Nasdaq exchange, signaling its intent to enter the public markets. The clinical-stage biopharmaceutical company plans to offer 7,812,500 shares of common stock at an anticipated price between $15.00 and $17.00 per share.

Offering Details

According to the company's filing, the IPO could raise up to $132.8 million at the high end of its proposed range. The company has applied to list its common stock on the Nasdaq Global Select Market under the proposed ticker symbol BLSM.

Key details from the filing include:

• Shares Offered: 7,812,500 common shares
• Price Range: $15.00 to $17.00 per share
• Proposed Ticker: BLSM
• Exchange: Nasdaq Global Select Market

Ad

The statement confirmed that no public market for BlossomHill's common stock has previously existed. The offering is contingent upon receiving approval for the listing from the exchange.

Underwriters and Market Implications

A syndicate of investment banks is managing the offering. The lead underwriters listed in the filing are J.P. Morgan, Leerink Partners, and Guggenheim Securities. LifeSci Capital and H.C. Wainwright & Co. are also serving as underwriters.

For a company like BlossomHill, an IPO is a critical step to raise capital, which is often used to fund costly clinical trials and further research and development. The success of the offering will be closely watched by investors as a gauge of market appetite for early-stage biotechnology ventures.